Umang Pharmatech Pvt. Ltd. offers various controlled release technologies including controlled release pellets, gelatin beads using hot melt extrusion, mouth dissolving films, and micro pellets. They provide formulation development, analytical testing, stability studies, regulatory dossier preparation, and contract manufacturing services. Their technologies can be used to develop various release profiles including extended, sustained, delayed, and enteric release formulations.
Warm Greetings from Chempro Pharma! Here is a brief presentation regarding our newest project/service offering - pharmaceutical product development. We have a highly specialized team that has worked with the likes of Novartis, Merck and many more market leaders within the pharmaceutical industry. Feel free to review this attachment and contact us at pharma@chemprogroup.net if you have any questions, thanks!
Formulation Science
Main steps of formulating a Drug Product
The role of Formulation Science in different
stages of Drug Development
Trends and challenges in formulation
development
Hi, I'm Presents a Research article for Journal club entitled with
"3D Printing: A Case of ZipDose® Technology –World’s First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product"
Reference (Source article):
1. West, Thomas & Bradbury, Thomas. (2018). 3D Printing: A Case of ZipDose® Technology - World's First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product: Process Engineering and Additive Manufacturing. https://doi.org/10.1002/9783527813704...
2. https://www.aprecia.com/technology/zipdose
Warm Greetings from Chempro Pharma! Here is a brief presentation regarding our newest project/service offering - pharmaceutical product development. We have a highly specialized team that has worked with the likes of Novartis, Merck and many more market leaders within the pharmaceutical industry. Feel free to review this attachment and contact us at pharma@chemprogroup.net if you have any questions, thanks!
Formulation Science
Main steps of formulating a Drug Product
The role of Formulation Science in different
stages of Drug Development
Trends and challenges in formulation
development
Hi, I'm Presents a Research article for Journal club entitled with
"3D Printing: A Case of ZipDose® Technology –World’s First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product"
Reference (Source article):
1. West, Thomas & Bradbury, Thomas. (2018). 3D Printing: A Case of ZipDose® Technology - World's First 3D Printing Platform to Obtain FDA Approval for a Pharmaceutical Product: Process Engineering and Additive Manufacturing. https://doi.org/10.1002/9783527813704...
2. https://www.aprecia.com/technology/zipdose
Pharmaceutical industry is constantly looking for ways to ensure and enhance product safety, quality and efficacy. However, drug recalls,
manufacturing failure cost, scale up issues and regulatory burden in recent past suggest otherwise. In traditional quality by testing (QbT) approach, the product quality and performance are predominantly ensured by end product testing, with limited understanding of the process and critical process parameters. Regulatory bodies are therefore focusing on implementing quality by design (QbD), a science based approach that improves
process understanding by reducing process variation and the enabling process-control strategies. In this regards, pharmaceutical industry is currently undergoing a significant transformation to streamline their R&D process, provide greater manufacturing flexibility and control, and to reduce regulatory burden. However, there is limited understanding and major concerns regarding the implementation of QbD principles in the
pharmaceutical arena. The objective of this review article is therefore to provide a comprehensive understanding on various aspects of QbD, along with addressing the concerns related to its implementation.
QBD Quality by design for Immediate release dosage formKushal Saha
Traditional approach of formulating a new drug product is an exhaustive task and involves a number of resources like man, money, time and experimental efforts. While, using this Quality by Design (QBD) approach one can get the pharmaceutical product of desired (best) quality with minimizing above resources as well as knowing the influence of one factor over the desired associated process. Hence aim of this study is the understanding of QBD approach to design product and manufacturing process to get desired pharmaceutical product. QBD follows the concepts of ICH guidelines (Q8, Q9 & Q10) which are essential for processing a pharmaceutical process. In this presentation we are going to focus upon QBD for immediate release dosage forms.
Quality by Design A Present to Future Perspectiveijtsrd
Quality by Design is the modern approach for quality of pharmaceuticals. This paper gives idea about the Pharmaceutical Quality by Design QbD and describes use of Quality by Design to ensure quality of Pharmaceuticals. The Quality by Design is described and some of its elements identified. Process parameters and quality attributes are identified for each unit operation. Benefits, opportunities and steps involved in Quality by Design of Pharmaceutical products are described. The aim of the pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. Quality cannot be tested into products but quality should be built in by design. It includes the Quality target product profile, critical quality attributes and key aspects of Quality by Design. It also gives comparison between product quality by end product testing and product quality by Quality by Design. The foundation of Quality by Design is ICH Guidelines. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, Q10 for pharmaceutical quality systems. It also gives application of Quality by Design in pharmaceutical development and manufacturing of pharmaceuticals. Mr. Rajesh Dumpala | Ms. Jaini Bhavsar | Mr. Chirag Patil "Quality by Design: A Present to Future Perspective" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-5 , August 2020, URL: https://www.ijtsrd.com/papers/ijtsrd32985.pdf Paper Url :https://www.ijtsrd.com/pharmacy/pharmaceutics/32985/quality-by-design-a-present-to-future-perspective/mr-rajesh-dumpala
The pharmaceutical Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based sound science and quality risk management.
Generic product development and technology transfer : At a glanceDr. Girish S Sonar
It’s honor to get invited as a speaker and to address “Pharma Formulation and Regulatory Symposium” organized by Merck Malaysia on 6th Sept, 2018 at Pullman Bangsar, Kuala Lumpur, Malaysia. The topic I presented was “Generic Product Development and Technology Transfer: At a Glance”. Scientists and industry experts from 31 Malaysia Pharma companies and Universities attended this symposium. The presentation covered challenges and remedies come across from product development to approval from regulatory agencies.
Pleasured to share desk with Dr. Torsten Schadendorf, Marketing Manager Merck Germany, Dr. Gudrun Birk, Head of Controlled Release, Merck Germany and Professor Tin Wui Wong, Universiti Teknologi MARA, Malaysia.
The pharmaceutical Quality by Design is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. Quality by Design is emerging to enhance the assurance of safe, effective drug supply to the consumer, and also offers promise to significantly improve manufacturing quality performance
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.
This presentation - Part II in the series- deals with the concepts of Quality Target Product Profile and Critical Quality attributes.This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web
Stabicon has been ambitiously established in 2010. Professionally managed with 75 scientists from diverse background expertise. Our organization is specialized in managing product quality process, upgrading and introducing advanced technology into products. we are proud to lay a foundation for prosperous future in prevention and cure segment, future medicine & FMCG business.
Pharmaceutical Industry Departments roles and responsibilities manasa life sc...ManasaLifeSciencesMa
Pharmaceutical Industry Departments and its roles and responsibilities were discussed. Product selection, Development, Manufacturing, Product approval, Marketing
Pharmaceutical industry is constantly looking for ways to ensure and enhance product safety, quality and efficacy. However, drug recalls,
manufacturing failure cost, scale up issues and regulatory burden in recent past suggest otherwise. In traditional quality by testing (QbT) approach, the product quality and performance are predominantly ensured by end product testing, with limited understanding of the process and critical process parameters. Regulatory bodies are therefore focusing on implementing quality by design (QbD), a science based approach that improves
process understanding by reducing process variation and the enabling process-control strategies. In this regards, pharmaceutical industry is currently undergoing a significant transformation to streamline their R&D process, provide greater manufacturing flexibility and control, and to reduce regulatory burden. However, there is limited understanding and major concerns regarding the implementation of QbD principles in the
pharmaceutical arena. The objective of this review article is therefore to provide a comprehensive understanding on various aspects of QbD, along with addressing the concerns related to its implementation.
QBD Quality by design for Immediate release dosage formKushal Saha
Traditional approach of formulating a new drug product is an exhaustive task and involves a number of resources like man, money, time and experimental efforts. While, using this Quality by Design (QBD) approach one can get the pharmaceutical product of desired (best) quality with minimizing above resources as well as knowing the influence of one factor over the desired associated process. Hence aim of this study is the understanding of QBD approach to design product and manufacturing process to get desired pharmaceutical product. QBD follows the concepts of ICH guidelines (Q8, Q9 & Q10) which are essential for processing a pharmaceutical process. In this presentation we are going to focus upon QBD for immediate release dosage forms.
Quality by Design A Present to Future Perspectiveijtsrd
Quality by Design is the modern approach for quality of pharmaceuticals. This paper gives idea about the Pharmaceutical Quality by Design QbD and describes use of Quality by Design to ensure quality of Pharmaceuticals. The Quality by Design is described and some of its elements identified. Process parameters and quality attributes are identified for each unit operation. Benefits, opportunities and steps involved in Quality by Design of Pharmaceutical products are described. The aim of the pharmaceutical development is to design a quality product and its manufacturing process to consistently deliver the intended performance of the product. Quality cannot be tested into products but quality should be built in by design. It includes the Quality target product profile, critical quality attributes and key aspects of Quality by Design. It also gives comparison between product quality by end product testing and product quality by Quality by Design. The foundation of Quality by Design is ICH Guidelines. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, Q10 for pharmaceutical quality systems. It also gives application of Quality by Design in pharmaceutical development and manufacturing of pharmaceuticals. Mr. Rajesh Dumpala | Ms. Jaini Bhavsar | Mr. Chirag Patil "Quality by Design: A Present to Future Perspective" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-5 , August 2020, URL: https://www.ijtsrd.com/papers/ijtsrd32985.pdf Paper Url :https://www.ijtsrd.com/pharmacy/pharmaceutics/32985/quality-by-design-a-present-to-future-perspective/mr-rajesh-dumpala
The pharmaceutical Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based sound science and quality risk management.
Generic product development and technology transfer : At a glanceDr. Girish S Sonar
It’s honor to get invited as a speaker and to address “Pharma Formulation and Regulatory Symposium” organized by Merck Malaysia on 6th Sept, 2018 at Pullman Bangsar, Kuala Lumpur, Malaysia. The topic I presented was “Generic Product Development and Technology Transfer: At a Glance”. Scientists and industry experts from 31 Malaysia Pharma companies and Universities attended this symposium. The presentation covered challenges and remedies come across from product development to approval from regulatory agencies.
Pleasured to share desk with Dr. Torsten Schadendorf, Marketing Manager Merck Germany, Dr. Gudrun Birk, Head of Controlled Release, Merck Germany and Professor Tin Wui Wong, Universiti Teknologi MARA, Malaysia.
The pharmaceutical Quality by Design is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management. Quality by Design is emerging to enhance the assurance of safe, effective drug supply to the consumer, and also offers promise to significantly improve manufacturing quality performance
FDA’s emphasis on quality by design began with the recognition that increased testing does not improve product quality (this has long been recognized in other industries).In order for quality to increase, it must be built into the product. To do this requires understanding how formulation and manufacturing process variables influence product quality.Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management.
This presentation - Part II in the series- deals with the concepts of Quality Target Product Profile and Critical Quality attributes.This presentation was compiled from material freely available from FDA , ICH , EMEA and other free resources on the world wide web
Stabicon has been ambitiously established in 2010. Professionally managed with 75 scientists from diverse background expertise. Our organization is specialized in managing product quality process, upgrading and introducing advanced technology into products. we are proud to lay a foundation for prosperous future in prevention and cure segment, future medicine & FMCG business.
Pharmaceutical Industry Departments roles and responsibilities manasa life sc...ManasaLifeSciencesMa
Pharmaceutical Industry Departments and its roles and responsibilities were discussed. Product selection, Development, Manufacturing, Product approval, Marketing
Segmentation, Targeting & Positioning: A Case Study of VitaciminDanny D. Kosasih
This document was presented when I was guest lecturing at FEUI on December 8th 2012. The purpose of this case study is to share the real practice and implementation of a Marketing Strategy concept.
Drug discovery and development is and always has been the most exciting part of clinical pharmacology. It is my attempt to compile the basic concepts from various books, articles and online journals. Feel free to comment.
Pharmaceutical marketing plan case studyMohamed Magdy
Pharmaceutical Marketing Plan Case Study
I can challenge you will never see such fully fledged Pharmaceutical Marketing Plan Case Study in the internet for FREE as I did in this case study!
Click here to ENJOY it: http://www.guerrillamarketer.com/pharmaceutical-marketing-plan-case-study/
pilot plant is a small system which is operated to find out about the behavior of a process before using it on a large industrial scale. so, this presentation tries to illustrate its objective and significance to understand the methodologies of various pharmaceutical dosage forms.
Pilot plant scale-up is a branch of the pharma companies in which a lab-scale formula is converted into a commercially viable product by creating a reliable manufacturing technique. The same techniques employed in dosage form Research and Development are adapted to multiple output volumes, frequently larger than those obtained during Research and Development. There is always a requirement for an intermediate batch scale describing techniques and imitating those in commercial manufacturing in any new or established pharmaceutical sector. This is accomplished by testing the formula’s ability to survive batch-scale and process changes.
Stages of scale up process mparm 1st year pharmaceutical process chemistryDhanashreeSarwan
Define Scale up process, need of Scale up technique, Stages of scale up process Bench\lab scale, pilot plant, large scale up technique, validation of large scale up process
The uploaded Power point presentation is of Industrial Pharmacy-II Unit-I (Topic - Pilot Plant Scale up Techniques). ppt is very useful for student of B.pharmacy
Pilot plant scaleup techniques | unit 1 | Industrial pharmacyFirst name Last name
General considerations-including
significance of personnel requirements, space requirements, raw materials,Pilot plant scale up
considerations for solids, liquid orals, semi solids and relevant documentation,
SUPAC guidelines,Introduction to platform technology
A qualified Diploma in chemical Technology 16.5 years of experience in Batch production processes, Industrial Plant Operations, Production Management with Documentation in the Pharmaceutical industries.(Anti-cardiotic drugs, Anti-dandruff drugs, Antibiotic drugs), Food Manufacturing (Nutrition’s)
A qualified Diploma in chemical Technology 16.5 years of experience in Batch production processes, Industrial Plant Operations, Production Management with Documentation in the Pharmaceutical industries.(Anti-cardiotic drugs, Anti-dandruff drugs, Antibiotic drugs), Food Manufacturing (Nutrition’s)
Visual effects for home and personal care.Umang Budhraja
Spheres and beads / Visual effects for Home and Personal care industry. Red, green, Blue, Black, Pink, purple, all beads enriched with vitamins, actives, flavors and fragrance. also surprise spheres with color changing beads. Also bio-degradable exfoliators.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Pharmaceutical Product development technology
1. PRODUCT DEVELOPMENT TECHNOLOGY
CONTROLLED RELEASE PELLETS
GELATIN BEADS HOT MELT EXTRUSION
MOUTH DISSOLVING FILM
Umang Pharmatech Pvt. Ltd.
STANDARD FEATURES : STANDARD FEATURES :
STANDARD FEATURES : STANDARD FEATURES :
Survey No. 146, H. No.1 (PT), Vasai Phata Highway Junction, Pelhar, Nh8, Vasai (E) - 401 208, Maharashtra (India).
Tel. : (+91-22) 30018900 / 30018915 - 98, Mob. : (+91) 986 723 6594, Fax : (+91-22) 30018908 / 30018913
E-mail : umang@umangpharmatech.com, Website : www.umangpharmatech.com / www.umangpharmaceuticals.com
www.umangpharmaceuticals.com
Consists of Strip forming polymers, plasticizers, API, flavoring & coloring agent, etc.
The delivery of drug via film, in-process onset of action, tailored to meet your requirements.
Enhance efficiency & safety profile of medicament.
Thin film is more stable, durable & quick dissolving than other forms.
Thin film improves dose accuracy empowered to liquid / syrup dosage form.
Ease of administration, beneficial for pediatric, geriatric & neurode generation disease.
Dissolving without made of water like patients with disorders / nausea.
Potential to develop sensitive drug targets.
Sublingual film delivers a convenient, quick dissolving therapeutic dose.
Drug contained by film, rapidly absorbs under the tounge to ensure compliance.
From commercial prospective it offers extend revenue life cycle for drug patent expiring soon.
Formulation development on a bench & pilot scale development.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
Innovative, advanced IR & MR formulation & process technology.
Dedicated project management with method development and validation.
Internal Technology transfer from laboratory to pilot plant to commercial technology.
Identifying the right key process parameters.
Full scale production of at least three batches.
Extended release (XR) or Long lasting (LA) allows for a decrease in dosing frequently.
SR- specific amount of drug release at time intervals.
Delayed or Enteric release formulation development is possible.
API release at a specific point in body based on PH or other char. depending on drug profile.
Drug release in the intestine formulated to release at a higher PH (more basic)
or drug release in stomach (more acidic).
Specific release pattern as per customer requirement can be developed.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
Formulation development on bench scale.
Bench & pilot scale development for your products.
Heat sensitive molecules also can also be processed with special processing attachments.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Technology transfer with equipment purchase & support if needed.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Hot melt pellets are also possible by attaching axillary equipments to the hot melt extruder.
Complete Technology transfer from product to pilot to large scale production possible.
Enhance solubility, bio for purely soluble drugs.
Ability to incorporate taste masking.
Broad selection of down stream process technology.
Granules for end in solid dosage form, incl. CR delivery formulations.
Tailored to meet your product requirements.
Short term accelerated physical stability studies before a full scale development program.
A range of proto type formulations are prepared under different process conditions.
Analytical techniques applied as appropriate to determine formulation & process parameters.
Improves the bio availability of purely water soluble & purely permeable compounds.
Enhance dose uniformity of potent compounds and minimize variability.
Reduce due time & benefit from a proven dosage form with stringent commercial success.
Oil and pellets can be encapsulated by this technology.
Gelatin and other core pellets can be made as per project needs.
We work strictly under confidentiality agreements with customer defined time lines.
Formulation development on a bench & pilot scale development.
Tailored to meet your product requirements.
Short term accelerated physical stability studies before a full scale development program.
A range of proto type formulations are prepared under different process conditions.
Analytical techniques applied as appropriate to determine formulation & process parameters.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Technology transfer with equipment purchase & support if needed.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Customer defined pellets can be made with customer ingredients / actives .
Complete Technology transfer from product to pilot to large scale production possible.
2. MICRO PELLETS
BEADS IN BEAD TECHNOLOGY
www.umangpharmaceuticals.com
Umang Pharmatech Pvt. Ltd.
PRODUCT DEVELOPMENT TECHNOLOGY
Survey No. 146, H. No.1 (PT), Vasai Phata Highway Junction, Pelhar, Nh8, Vasai (E) - 401 208, Maharashtra (India).
Tel. : (+91-22) 30018900 / 30018915 - 98, Mob. : (+91) 986 723 6594, Fax : (+91-22) 30018908 / 30018913
E-mail : umang@umangpharmatech.com, Website : www.umangpharmatech.com / www.umangpharmaceuticals.com
STANDARD FEATURES :
STANDARD FEATURES : STANDARD FEATURES :
Micro pellets technology for 100 / 200 / 300 / 400 / 500 micron sizes.
Dedicated project management with method development and validation.
Internal Technology transfer from laboratory to pilot plant to commercial technology.
Identifying the right key process parameters.
Full scale production of at least three batches.
Controlled drug delivery of the products is possible with micro pellets.
Can be compressed into tablets.
Delayed or Enteric release formulation development is possible.
API release at a specific point in body based on PH or other char. depending on drug profile.
Micro pellets have a higher bulk density compared to API or granules.
Fill weight of the product is higher in the capsules due to smaller size.
Dedicated equipments for development.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
Pulsed drug delivery is a mixture of different release pattern are mixed.
Dedicated project management with method development and validation.
Internal Technology transfer from laboratory to pilot plant to commercial technology.
Identifying the right key process parameters.
Full scale production of at least three batches.
Controlled drug delivery of the products is possible with micro pellets.
Dedicated equipments for development.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
Tailored to meet your product requirements.
A range of proto type formulations are prepared under different process conditions.
Analytical techniques applied as appropriate to determine formulation & process parameters.
PULSED DRUG DELIVERY
STANDARD FEATURES :
MUPS TECHNOLOGY
Micro pellets technology for 100 / 200 / 300 / 400 / 500 micron sizes.
The pellets are being put into another large pellet size by a special process.
This technology avoids interaction between molecules.
Dedicated project management with method development and validation.
Internal Technology transfer from laboratory to pilot plant to commercial technology.
Identifying the right key process parameters.
Full scale production of at least three batches.
Controlled drug delivery of the products is possible with micro pellets.
Can be compressed into tablets.
Delayed or Enteric release formulation development is possible.
API release at a specific point in body based on PH or other char. depending on drug profile.
Micro pellets have a higher bulk density compared to API or granules.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
Micro pellets technology for 100 / 200 / 300 / 400 / 500 micron sizes.
The pellets are being put into another large tablet.
This technology avoids interaction between molecules.
Dedicated project management with method development and validation.
Internal Technology transfer from laboratory to pilot plant to commercial technology.
Identifying the right key process parameters.
Full scale production of at least three batches.
Controlled drug delivery of the products is possible with micro pellets.
Can be compressed into tablets.
Delayed or Enteric release formulation development is possible.
API release at a specific point in body based on PH or other char. depending on drug profile.
Micro pellets have a higher bulk density compared to API or granules.
Short term accelerated physical stability studies before a full scale development program.
Dossier preparation per product with scale up parameters for pilot and production scale.
Contract manufacturing for the products in our GMP approved facility.
Non-exclusive / exclusive arrangement to deliver treatments for your molecule.
Complete Technology transfer from product to pilot to large scale production possible.
